Pacific Edge (NZE:PEB, ASX:PEB) reported a 6.8% increase in tests processed at its laboratories in the fourth quarter of fiscal 2025 compared with the prior three-month period, according to a Friday filing with the Australian and New Zealand bourses.

Total laboratory throughput rose to 7,577 tests from 7,092 tests between the third and fourth fiscal quarters.

However, total volumes for the full fiscal year ended March declined nearly 12% to 28,894 tests from 32,633 in the prior fiscal year. The decline reflected lower sales force due to the uncertainty over Medicare coverage of Cxbladder, per the filing.

Pacific Edge's shares were up 3% in New Zealand and by 4% in Australia in recent Friday trade.